Sleep Apnea Device Maker ResMed Is A Durable MedTech, With Positive Fundamentals, Says Analyst
On Thursday, ResMed Inc RMD reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus of $2.04.
ResMed's Stock Rises on Q1 Earnings and Revenue Beat, Margins Expand
RMD's stellar first-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.
ResMed Inc. (RMD) Q1 2025 Earnings Call Transcript
ResMed Inc. (NYSE:RMD ) Q1 2025 Earnings Conference Call October 24, 2024 4:30 PM ET Company Participants Amy Wakeham - Chief Investor Relations Officer Michael Farrell - Chairman and Chief Executive Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Laura Sutcliffe - UBS Craig Wong-Pan - RBC David Low - JPMorgan Saul Hadassin - Barrenjoey Capital Anthony Petrone - Mizuho Daniel Hurren - MST Marquee Mike Matson - Needham & Company Brett Fishbin - KeyBanc Capital Markets Suraj Kalia - Oppenheimer Lyanne Harrison - Bank of America Andrew Paine - CLSA Operator Hello, and welcome to the Q1 Fiscal Year 2025 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call.
ResMed (RMD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for ResMed (RMD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ResMed (RMD) Surpasses Q1 Earnings and Revenue Estimates
ResMed (RMD) came out with quarterly earnings of $2.20 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $1.64 per share a year ago.
ResMed beats quarterly profit estimates on strong demand for its sleep apnea devices
ResMed beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its devices used for sleep apnea treatment.
ResMed Adds To Its Recent Sprint, Shrugging Off Worries Tied To Obesity Drugs
ResMed stock bounded higher late Thursday after the CPAP-maker shrugged off worries popular weight-loss drugs would hammer its top line.
Unveiling ResMed (RMD) Q1 Outlook: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ResMed (RMD) is an Incredible Growth Stock: 3 Reasons Why
ResMed (RMD) could produce exceptional returns because of its solid growth attributes.
Is ResMed Stock a Smart Addition to Your Portfolio Right Now?
RMD's robust mask business and efforts to boost its SaaS business are encouraging.
ResMed (RMD) Earnings Expected to Grow: Should You Buy?
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
